
Terry A. Wallace
Examiner (ID: 8615, Phone: (571)272-2630 , Office: P/2916 )
| Most Active Art Unit | 2916 |
| Art Unit(s) | 2912, 2900, 2902, 2916 |
| Total Applications | 11456 |
| Issued Applications | 11361 |
| Pending Applications | 3 |
| Abandoned Applications | 90 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19065712
[patent_doc_number] => 20240100138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => IL-15-BASED FUSIONS TO IL-12 AND IL-18
[patent_app_type] => utility
[patent_app_number] => 18/526598
[patent_app_country] => US
[patent_app_date] => 2023-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29945
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18526598
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/526598 | IL-15-based fusions to IL-12 and IL-18 | Nov 30, 2023 | Issued |
Array
(
[id] => 19172564
[patent_doc_number] => 20240158538
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => VISTA ANTIGEN-BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 18/518192
[patent_app_country] => US
[patent_app_date] => 2023-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70336
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18518192
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/518192 | VISTA ANTIGEN-BINDING MOLECULES | Nov 21, 2023 | Pending |
Array
(
[id] => 19556474
[patent_doc_number] => 20240368266
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/508567
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37310
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508567
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/508567 | IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF | Nov 13, 2023 | Pending |
Array
(
[id] => 19172516
[patent_doc_number] => 20240158490
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => GOUT FLARE PREVENTION METHODS USING IL-1BETA BLOCKERS
[patent_app_type] => utility
[patent_app_number] => 18/506701
[patent_app_country] => US
[patent_app_date] => 2023-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12899
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506701
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/506701 | GOUT FLARE PREVENTION METHODS USING IL-1BETA BLOCKERS | Nov 9, 2023 | Pending |
Array
(
[id] => 19300030
[patent_doc_number] => 20240228599
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-11
[patent_title] => ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/504416
[patent_app_country] => US
[patent_app_date] => 2023-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504416
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/504416 | ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | Nov 7, 2023 | Pending |
Array
(
[id] => 19052254
[patent_doc_number] => 20240094223
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => BIOMARKER COMBINATIONS TO SIMULTANEOUSLY EVALUATE NON-ALCOHOLIC STEATOHEPATITIS AND HEPATIC FIBROSIS STATUS
[patent_app_type] => utility
[patent_app_number] => 18/502243
[patent_app_country] => US
[patent_app_date] => 2023-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16293
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502243
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/502243 | Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status | Nov 5, 2023 | Issued |
Array
(
[id] => 19020194
[patent_doc_number] => 20240076365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 18/502188
[patent_app_country] => US
[patent_app_date] => 2023-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18288
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502188
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/502188 | Gremlin-1 crystal structure and inhibitory antibody | Nov 5, 2023 | Issued |
Array
(
[id] => 18987780
[patent_doc_number] => 20240059749
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10
[patent_app_type] => utility
[patent_app_number] => 18/501741
[patent_app_country] => US
[patent_app_date] => 2023-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501741
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/501741 | Dual cytokine fusion proteins comprising IL-10 | Nov 2, 2023 | Issued |
Array
(
[id] => 20562031
[patent_doc_number] => 12564621
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-03
[patent_title] => Interleukin-18 variants and methods of use
[patent_app_type] => utility
[patent_app_number] => 18/501210
[patent_app_country] => US
[patent_app_date] => 2023-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 56
[patent_figures_cnt] => 83
[patent_no_of_words] => 55643
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 376
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501210
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/501210 | Interleukin-18 variants and methods of use | Nov 2, 2023 | Issued |
Array
(
[id] => 19018933
[patent_doc_number] => 20240075104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => INTERLEUKIN-18 VARIANTS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/501206
[patent_app_country] => US
[patent_app_date] => 2023-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59065
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501206
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/501206 | Interleukin-18 variants and methods of use | Nov 2, 2023 | Issued |
Array
(
[id] => 20129170
[patent_doc_number] => 12371472
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Multimeric IL-15 soluble fusion molecules and methods of making and using same
[patent_app_type] => utility
[patent_app_number] => 18/498430
[patent_app_country] => US
[patent_app_date] => 2023-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 113
[patent_figures_cnt] => 183
[patent_no_of_words] => 43728
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18498430
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/498430 | Multimeric IL-15 soluble fusion molecules and methods of making and using same | Oct 30, 2023 | Issued |
Array
(
[id] => 19202858
[patent_doc_number] => 20240174757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => CD131 BINDING PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/497461
[patent_app_country] => US
[patent_app_date] => 2023-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68020
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497461
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/497461 | CD131 BINDING PROTEINS AND USES THEREOF | Oct 29, 2023 | Pending |
Array
(
[id] => 19248764
[patent_doc_number] => 20240199751
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 18/495182
[patent_app_country] => US
[patent_app_date] => 2023-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25309
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18495182
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/495182 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | Oct 25, 2023 | Pending |
Array
(
[id] => 19265401
[patent_doc_number] => 20240209100
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => HETEROMERIC AGONISTIC ANTIBODIES TO IL-18 RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 18/382871
[patent_app_country] => US
[patent_app_date] => 2023-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29189
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382871
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/382871 | HETEROMERIC AGONISTIC ANTIBODIES TO IL-18 RECEPTOR | Oct 22, 2023 | Pending |
Array
(
[id] => 19067287
[patent_doc_number] => 20240101713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => Bi-Specific Fusion Proteins
[patent_app_type] => utility
[patent_app_number] => 18/483308
[patent_app_country] => US
[patent_app_date] => 2023-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35341
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18483308
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/483308 | Bi-Specific Fusion Proteins | Oct 8, 2023 | Pending |
Array
(
[id] => 20213582
[patent_doc_number] => 12410224
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => IL-15-based fusions to IL-7 and IL-21
[patent_app_type] => utility
[patent_app_number] => 18/472053
[patent_app_country] => US
[patent_app_date] => 2023-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 54
[patent_figures_cnt] => 87
[patent_no_of_words] => 29079
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472053
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/472053 | IL-15-based fusions to IL-7 and IL-21 | Sep 20, 2023 | Issued |
Array
(
[id] => 18879127
[patent_doc_number] => 20240002496
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA
[patent_app_type] => utility
[patent_app_number] => 18/244459
[patent_app_country] => US
[patent_app_date] => 2023-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16573
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18244459
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/244459 | INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA | Sep 10, 2023 | Abandoned |
Array
(
[id] => 20343146
[patent_doc_number] => 12466868
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-11
[patent_title] => Engineered proteins to enhance sensitivity of a cell to IL-2
[patent_app_type] => utility
[patent_app_number] => 18/460452
[patent_app_country] => US
[patent_app_date] => 2023-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 15
[patent_no_of_words] => 16586
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18460452
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/460452 | Engineered proteins to enhance sensitivity of a cell to IL-2 | Aug 31, 2023 | Issued |
Array
(
[id] => 19172546
[patent_doc_number] => 20240158520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 18/459292
[patent_app_country] => US
[patent_app_date] => 2023-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28074
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459292
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/459292 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY | Aug 30, 2023 | Abandoned |
Array
(
[id] => 18902999
[patent_doc_number] => 20240018484
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESS
[patent_app_type] => utility
[patent_app_number] => 18/452952
[patent_app_country] => US
[patent_app_date] => 2023-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18138
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452952
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/452952 | METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESS | Aug 20, 2023 | Pending |